NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer

Archives of Toxicology

Volumn 73, Issue 10-11, 2000, Pages 528-531

  Harth, V ^a   Donat, S ^a   Ko, Y ^c   Abel, J ^a   Vetter, H ^c   Bruning T ^b  

^a Heinrich Heine Universat Dusseldorf   (Germany)

^b LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Colorectal cancer; NQO1 polymorphism; Real time PCR

Indexed keywords

CIGARETTE SMOKE; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME POLYMORPHISM; GENE ACTIVITY; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOKING;

EID: 0033384268     PISSN: 03405761     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002040050004     Document Type: Article

References (12)

1. Chen H, Lum A, Seifried A, Wilkens LR, Le Marchand L (1999) Association of the NAD(P)H: quinone oxidoreductase 609 C→T polymorphism with a decreased lung cancer risk. Cancer Res 59: 3045-3048
2. Joseph P, Jaiswal AK (1994) NAD(P)H: quinone oxidoreductasel (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc Natl Acad Sci USA 91: 8413-8417
3. Kuehl BL, Paterson JW, Peacock JW, Paterson MC, Rauth AM (1995) Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer 72: 555-561
4. Longuemaux S, Delomenie C, Gallou C, Mejean A, Vincent-Viry M, Bouvier R, Droz D, Krishnamoorthy R, Galteau MM, Junien C, Beroud C, Dupret JM (1999) Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res 59: 2903-2908
5. Radjendirane V, Joseph P, Lee YH, Kimura S, Klein-Szanto AJ, Gonzalez FJ, Jaiswal AK (1998) Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem 273: 7382-7389
6. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH (1995) Identification of an NAD(P)H: quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 5: 199-206
7. Schulz WA, Krummeck A, Rosinger I, Eickelmann P, Neuhaus C, Ebert T, Schmitz-Drager BJ, Sies H (1997) Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 7: 235-239
8. Schulz WA, Krummeck A, Rosinger I, Schmitz-Drager BJ, Sies H (1998) Predisposition towards urolithiasis associated with the NQO1 null-allele. Pharmacogenetics 8: 453-454
9. Steiner M, Hillenbrand M, Borkowsi M, Seiter H, Schuff-Werner P (1999) 609 C→T polymorphism in NAD(P)H: quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia. Cancer Lett 135: 67-71
10. Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D, Gibson NW (1992) NAD(P)H: quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52: 797-802
11. Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D (1997) Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 75: 69-75
12. Wiencke JK, Spitz MR, McMillan A, Kelsey KT (1997) Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev 6: 87-92